
May 19 (Reuters) -
APNIMED ANNOUNCES POSITIVE TOPLINE RESULTS IN THE FIRST LANDMARK PHASE 3 CLINICAL TRIAL OF AD109, AN INVESTIGATIONAL ONCE-DAILY ORAL PILL FOR OBSTRUCTIVE SLEEP APNEA
APNIMED: AD109 MET PRIMARY ENDPOINT
APNIMED: EXPECTS TOPLINE RESULTS IN Q3'25 FROM SECOND PHASE 3 CLINICAL TRIAL, LUNAIRO, PLANS TO SUBMIT AN NDA TO U.S. FDA FOR AD109 BY EARLY 2026
APNIMED: AD109 GENERALLY WELL-TOLERATED & MOST COMMON ADVERSE EVENTS CONSISTENT WITH EARLIER AD109 CLINICAL TRIALS